adefovir dipivoxil

This page contains recent news articles, when available, and an overview of adefovir dipivoxil but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.

B형 간염 1차 약제 내성, '헵세�?�정 10mg' 급여  -  ‎Aug 12, 2009‎
...�?승정 기�? �?메디컬헤럴드신문】앞으로 B형 간염 1차치료제(lamivudine, clevudine, entecavir 0.5mg)�?� 내성�?� 발현�?� 경우 adefovir dipivoxil 경구제(품명 메디컬헤럴드

9월부터 �??경 후 호르몬제 등 약제 5항목 급여신설  -  ‎Aug 27, 2009‎
...했고 △B형 간염 1차 치료제(lamivudine, clevudine, entecavir 0.5mg) 내성�?� 발현�?� 경우 adefovir dipivoxil 경구제(품명: 헵세�?�정 10mg) 요양급여�?� �?�정했다. 메디포뉴스

HEPATITES ACTUALITE : Le traitement de l'hépatite B en 2008  -  ‎Mar 6, 2009‎
Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy. ARCAT

Clinical Trials Update: Jan. 26, 2009  -  Jan 26, 2009
If you are 18 or older, have hepatitis B, have never been treated with a nucleoside analogue such as Hepsera (adefovir dipivoxil), and meet additional Washington Post,

Gilead has Strong 4Q, but US HIV Drug Sales Down  -  Jan 28, 2009
The company's other hepatitis B drug, Hepsera (adefovir dipivoxil), generated sales of $76 million in the fourth quarter, which Washington noted was a 1 TMCnet

Entecavir: Resistance in Nucleoside-naive Chronic Hepatitis B Patients  -  Jan 12, 2009
Tenofovir disoproxil fumarate (TDF) for the treatment of HBeAg-positive chronic hepatitis B: week 72 TDF data and week 24 adefovir dipivoxil switch data Medscape

Gilead Sciences Announces Record Fourth Quarter and Full Year 2008 ...  -  Jan 28, 2009
Other antiviral product sales, including Viread® (tenofovir disoproxil fumarate), Hepsera® (adefovir dipivoxil) and Emtriva® (emtricitabine), increased five Lifescience-online,

*vwd/BUSINESS WIRE: Gilead Sciences gibt Rekord-Finanzergebnisse ...  -  Jan 30, 2009
Weitere Antiviralprodukte Der Umsatz bei den sonstigen Antiviralprodukten wie Viread^® (Tenofovir Disoproxil Fumarat), Hepsera^® (Adefovir Dipivoxil) und ddp-direkt.de (press release),

Gilead Sciences annonce des résultats financiers record pour le ...  -  Jan 29, 2009
Les ventes d’autres produits antiviraux, y compris celles de Viread ® (ténofovir disoproxil fumarate), d’Hepsera ® (adefovir dipivoxil) et d’Emtriva Boursier.com (Communiqué de presse),

Maga ellen játszott a gyártó  -  Jan 21, 2009
...napi egy adagos Vireadot (hatóanyag: tenofovil disproxil fumarate) és saját fejlesztése, a Hepsera (adefovir dipivoxil) ellenében tesztelte. Weborvos,

Gilead Sciences gibt Rekord-Finanzergebnisse für viertes Quartal ...  -  Jan 30, 2009
Der Umsatz bei den sonstigen Antiviralprodukten wie Viread ® (Tenofovir Disoproxil Fumarat), Hepsera ® (Adefovir Dipivoxil) und Emtriva ® (Emtricitabin) Business Wire (press release),

Tenofovir Disoproxil Fumarate versus Adefovir Dipivoxil for ...  -  Dec 3, 2008
Results At week 48, in both studies, a significantly higher proportion of patients receiving tenofovir DF than of those receiving adefovir dipivoxil had New England Journal of Medicine (subscription),

Tenofovir May Be More Effective Than Adefovir for Chronic ...  -  Dec 8, 2008
Compare the efficacy of tenofovir disoproxil fumarate vs adefovir dipivoxil in patients with chronic hepatitis B virus infection. Medscape

Data Demonstrating Significant Efficacy of Viread® in Treating ...  -  Dec 3, 2008
For patients with lamivudine-resistant HBV, adefovir dipivoxil should be used in combination with lamivudine. For all patients, consider modifying treatment WELT ONLINE,

부광 '레보비르' 성장�?�력 본격화  -  Dec 22, 2008
Entecavir 경구제(바�?��?�루드)는 0.5mg �?� 경우 기존�?� 최대 3년간�?� 급여�?�정�?� 하�?�, 3년�?� 초과해 투여하는 경우�?는 Adefovir dipivoxil 과 �?��?�하게 3323�?까지 메디파나뉴스,

Epatite B cronica: terapia farmacologica  -  Dec 18, 2008
Adefovir dipivoxil ( Hepsera ) ha un profilo di resistenza di prima linea superiore, ed è attivo contro i virus HVB resistenti alla Lamivudina. XagenaSalute,

�?�귀�?�약품 엘�?�프�?�제 등 3품목 급여�?�정  -  Dec 22, 2008
...�?� 밖�?�?� 간장질환 용제 adefovir dipivoxil 경구제(품명: 헵세�?�정), clevudine 경구제(품명: 레보비르캡�?), entecavir경구제(품명: 바�?��?�루드정 0.5mg, 시럽), 메디�?�뉴스,

New England Journal of Medicine veröffentlicht Daten, die hohe ...  -  Dec 5, 2008
Bei Patienten mit Lamivudin-resistenter HBV sollte Adefovir Dipivoxil in Kombination mit Lamivudin angewandt werden. Bei allen Patienten sollte eine WELT ONLINE,

Publicados en el New England Journal of Medicine datos que ...  -  Dec 5, 2008
...otro de los medicamentos más recetados para el VHB en Estados Unidos, Hepsera® (adefovir dipivoxil), también desarrollado y comercializado por Gilead. Business Wire (press release),

Data, gepubliceerd in New England Journal of Medicine ...  -  Dec 4, 2008
...orale medicatie voor HBV in de Verenigde Staten, Hepsera® (adefovir dipivoxil), dat eveneens werd ontwikkeld en op de markt wordt gebracht door Gilead. Business Wire (press release),

Tenofovir disoproxil nel trattamento dell’epatite B cronica  -  Dec 2, 2008
I pazienti in entrambi gli studi sono stati assegnati a ricevere Tenofovir disoproxil ( Viread ) oppure Adefovir dipivoxil ( Hepsera ). XagenaSalute,

La rivista New England Journal of Medicine pubblica dati che ...  -  Dec 3, 2008
...dimostrano che Viread è considerevolmente più efficace per il trattamento del virus che causa l’epatite B cronica di Hepsera ® (adefovir dipivoxil), Business Wire (press release),

Gilead Announces Two-Year Data from Pivotal Phase III Studies ...  -  Nov 1, 2008
Patients in both studies were originally randomized to receive Viread or Hepsera ® (adefovir dipivoxil). After the completion of 48 weeks of randomized WELT ONLINE,

Telaprevir Takes Center Stage as New HCV Approaches Advance  -  Nov 3, 2008
After 48 weeks of treatment with Viread or Gilead's Hepsera (adefovir dipivoxil), all patients in both trials were rolled over onto Viread monotherapy. BioWorld Online,

Gilead Sciences presents positive data from Phase III HBV studies  -  Nov 3, 2008
Patients in both studies were originally randomized to receive Viread or Hepsera (adefovir dipivoxil). After the completion of 48 weeks of randomized Trading Markets (press release),

Gilead gibt Daten von zweijähriger, zulassungsrelevanter Phase-III ...  -  Nov 3, 2008
Die Patienten beider Studien wurden ursprünglich mittels Randomisierungsverfahren zur Behandlung mit Viread oder Hepsera® (Adefovir Dipivoxil) ausgewählt. WELT ONLINE,

Gilead Sciences Announces Third Quarter 2008 Financial Results  -  Oct 16, 2008
Sales of Hepsera(R) (adefovir dipivoxil) for chronic hepatitis B increased 15 percent to $91.2 million for the third quarter of 2008 from $79.3 million in Centre Daily Times,

Oral treatment with antiviral drug combinations effective against ...  -  Oct 17, 2008
The researchers evaluated the antiviral effects of orally administered adefovir dipivoxil (ADV) or tenofovir disoproxil fumarate (TDF) alone, Newspost Online,

*vwd/BUSINESS WIRE: Gilead Sciences gibt die Finanzergebnisse des ...  -  Oct 19, 2008
Hepsera Die Produktverkäufe von Hepsera^® (Adefovir Dipivoxil) für chronische Hepatitis B erreichten im dritten Quartal 2008 USD 91,2 Millionen, ddp-direkt.de,

SL Pharma Wins SFDA Approval for New Drug and a Clinical Trial  Aug 29, 2008
Adefovir dipivoxil, the drug newly approved for marketing, is aimed at hepatitis B. It is currently available from more than 10 China pharmaceuticalSeeking Alpha,

FDA Safety Changes: Ambien, Primaxin IM/IV, Hepsera  Aug 28, 2008
Identify recommendations to reduce the risk for resistance to adefovir dipivoxil. Disclosure: Yael Waknine has disclosed no relevant financial relationshipsMedscape (subscription)

The Role of Monotherapy vs Combination Therapy for Chronic Hepatitis B  Aug 28, 2008
Tenofovir disoproxil fumarate (TDF) for the treatment of HBeAg-positive chronic hepatitis B: week 72 TDF data and week 24 adefovir dipivoxil switch dataMedscape (subscription)

FDA Approvals: Viread and Cancidas  Aug 21, 2008
...with compensated liver function who were randomly assigned to receive 300 mg of tenofovir daily or 10 mg of adefovir dipivoxil daily (Hepsera; Gilead).Medscape (subscription)

China Biotech Week in Review: First Overseas FDA Office  Sep 1, 2008
Adefovir dipivoxil, the new hepatitis B drug, is already marketed by 10 China biopharmas, but SL Pharma is one of only three to have permission toSeeking Alpha,

Clinical Briefs  Sep 3, 2008
...randomized and double-blind Phase III clinical trials, which compared Viread to Gilead's Hepsera (adefovir dipivoxil) over 48 weeks of treatment.U.S. Medicine,

FDA aprova Viread para tratamento da hepatite B crónica  Aug 28, 2008
...tolerabilidade e eficácia do fármaco em comparação com o Hepsera (adefovir dipivoxil), também da Gilead, em pacientes com a doença.Farmacia,

HIV치료제 Viread�? 만성 B간염 치료 �?�?��? 추가  Aug 17, 2008
...질레드사�?� 헵세�?�(adefovir dipivoxil) 역시 미국�?서 만성 B 간염 치료�? 가장 많�?� 처방�?�고 있다. 2개�?� 제3�? 임�? 실험�?서 Viread와 헵세�?�를 비�?한 결과 만성메디�?�뉴스,

VIREAD療效顯著�?�准上市  Sep 6, 2008
...�?�?�48周的治療後，VIREAD比�?�一種乙型�?炎病毒藥物HEPSERA(adefovir dipivoxil世界日報,

Zoek in het archief  -  Jul 17, 2008
Hepsera Sales of Hepsera(R) (adefovir dipivoxil) for chronic hepatitis B were $90.4 million for the second quarter of 2008, a 20 percent increase from $75.2 Netherlands Corporate News (persbericht),

Pharmasset Announces Initiation of Combination Study of Clevudine ...  -  Jul 8, 2008
...trials designed to demonstrate the superiority of clevudine 30mg over Hepsera(R) (adefovir dipivoxil) 10mg, each administered once-daily as monotherapy. CNNMoney.com (press release)

Actu des traitements  -  Jul 31, 2008
...(interféron alpha 2a) et Viraféron® (alpha 2b), Zeffix® (lamivudine) et Hepsera® (adefovir dipivoxil), un autre antiviral en prise quotidienne unique. Act Up-Paris,

*vwd/BUSINESS WIRE: Gilead Sciences gibt die Finanzergebnisse des ...  -  Jul 21, 2008
Hepsera Die Produktverkäufe von Hepsera^® (Adefovir Dipivoxil) für chronische Hepatitis B erreichten im zweiten Quartal 2008 USD 90,4 Millionen, ddp-direkt.de,

Normativa. BOE  -  Jul 9, 2008
...que se publica adjudicación definitiva de suministro de Anfotericina B, Tenofovir Disoproxil, Tenofovir Disoproxil+Emtricitabina y Adefovir Dipivoxil. EcoDiario.es,

Safer, better medication for Hepatitis B identified  -  Jun 27, 2008
Adefovir dipivoxil is another treatment option, however, virologic suppression is not optimal. A third drug, Entecavir, has been shown to be a safe and Sify,

Safer, More Efficient Medication for Hepatitis B  -  Jul 1, 2008
Adefovir dipivoxil is another treatment option, but virologic suppression is not optimal. A third drug, Entecavir, has been shown to be a safe and effective EndoNurse,

Hepatitis B Patients on Pegasys Achieve Positive Treatment Response  -  May 6, 2008
Long-term efficacy and safety of adefovir dipivoxil (ADV) 10 mg in HBeAg+ chronic hepatitis B (CHB) patients: increasing serologic, virologic and EndoNurse,

Gilead Sciences Announces First Quarter 2008 Financial Results  -  Apr 16, 2008
Hepsera(R) (adefovir dipivoxil) sales were $83.0 million for the first quarter of 2008, a 16 percent increase from $71.3 million in the first quarter of Centre Daily Times,

Treatment of the HBV-Infected Patient: When to Start, When to Stop ...  -  Feb 27, 2008
Sustained biochemical and virological remission after discontinuation of 4 to5 years of adefovir dipivoxil (ADV) treatment in HBeAg-negative chronic Medscape (subscription)

Gilead Sciences Announces Fourth Quarter and Full Year 2007 ...  -  Jan 23, 2008
Hepsera for Chronic Hepatitis B Hepsera® (adefovir dipivoxil) sales were $76.9 million for the fourth quarter of 2007, a 17 percent increase from $65.9 WELT ONLINE,

Gilead Sciences Announces Fourth Quarter and Full Year 2007 ...  -  Jan 24, 2008
Hepsera® (adefovir dipivoxil) sales were $76.9 million for the fourth quarter of 2007, a 17 percent increase from $65.9 million in the fourth quarter of Lifescience-online,

Telbivudine May Be More Effective Than Lamivudine for Chronic ...  -  19 Dec 2007
Current options for the treatment of chronic HBV infection include multiple types of interferon, adefovir dipivoxil, and lamivudine. Medscape (subscription)

Evolution of Therapy for Chronic Hepatitis B: Progressing from the ...  -  Dec 3, 2007
In this issue, Chan and colleagues (17) compared the antiviral efficacy of telbivudine and adefovir dipivoxil at 24 weeks of therapy. Annals of Internal Medicine

2007 Annual General Meeting Presentation  -  Dec 10, 2007
Development Trails w/SFDA Launch YouHeDing (anti-HBV drug) Adefovir Dipivoxil Approved 2003 2005 2007 Anti-HBV drug program L-nucleotide Pre-clinical Sydney Morning Herald,

Gilead HIV Viread Bettered Gilead HBV Hepsera In Curing HBV  -  Nov 3, 2007
On the other hand, Gilead has another product Hepsera, or adefovir dipivoxil, which is already approved for treating the liver infection in adults. eFluxMedia

Gilead Adds To Fibrotic Disease Pipeline In $202M Deal With LGLS  -  Nov 7, 2007
On the liver side, Gilead markets Hepsera (adefovir dipivoxil) for hepatitis B virus (HBV) infection and, earlier this year, reported promising top-line BioWorld Online,

Gilead's drug promising in hepatitis B  -  Nov 6, 2007
By Staff Writer Studies 102 and 103 compare Viread to Gilead's Hepsera (adefovir dipivoxil) among patients with hbeag-negative (presumed pre-core mutant) Pharmaceutical Business Review

Fewer Hepatitis B Patients Need Liver Transplants  -  Nov 5, 2007
The four antiviral medicines that are used to treat hepatitis B are adefovir dipivoxil, entecavir, lamivudine, and telbivudine. Associated Content,

Gilead looks to put Viread up against B-MS' Baraclude as a ...  -  Nov 5, 2007
They compared Viread (tenofovir) to Hepsera (adefovir dipivoxil) among patients with hbeag-negative and hbeag-positive hepatitis B, respectively. Pharma Times (subscription),

Gilead Sciences Says HBV Drug Viread Shows Superior Efficacy ...  -  Nov 2, 2007
Studies 102 and 103, which evaluate the safety and efficacy of once-daily Viread, compare Viread to Gilead's Hepsera or adefovir dipivoxil among patients RTT News,

Gilead Announces 48-Week Data from Two Pivotal Phase III Studies ...  -  Nov 2, 2007
Studies 102 and 103 compare Viread to Gilead’s Hepsera ® (adefovir dipivoxil) among patients with hbeag-negative (presumed pre-core mutant) chronic Business Wire (press release),

Nationwide Decrease in the Need for Liver Transplant  -  Nov 2, 2007
...four oral antiviral medications have been approved by the Food and Drug Administration for treatment of hepatitis B: lamivudine, adefovir dipivoxil, Newswise (press release)

Gilead Sciences Announces Third Quarter 2007 Financial Results  -  Oct 19, 2007
Hepsera(R) (adefovir dipivoxil) and ambisome(R) (amphotericin B) liposome for injection also experienced solid sales growth compared to the same quarter PharmaLive.com (press release),

Gilead Asks Viread Approval In US, Europe Against HBV  -  Oct 13, 2007
...based Gilead's Hepsera (adefovir dipivoxil). Top-line data were disclosed in June, and details are due at the annual meeting of the American Association for BioWorld Online,

News From The Annals Of Internal Medicine  -  Oct 2, 2007
A 52-week, randomized trial involving 135 people with chronic hepatitis B virus (HBV) compared an older drug adefovir dipivoxil and a newer drug, Medical News Today (press release),

Pharmasset Commences Dosing in Phase 3 Registration Studies of ...  -  Oct 1, 2007
...trials designed to demonstrate the superiority of clevudine 30mg over Hepsera (adefovir dipivoxil) 10mg, each administered once-daily as monotherapy. CNNMoney.com

Small Caps Monitor: SEA, CCY, MNC and AGX  -  Oct 3, 2007
The company said it has recruited staff to sell YouHeDing (adefovir dipivoxil) in key areas in China. "The patient population for hepatitis B virus (HBV) in ABN Newswire (press release),

Gilead Sciences Marketing Applications In US And European Union ...  -  Oct 11, 2007
These studies evaluate the efficacy, safety and tolerability of Viread compared to Gilead's Hepsera or adefovir dipivoxil. Eugene Schiff, Chief of the RTT News,

[an error occurred while processing this directive] :

Disclaimer:

Contact a physician with regard to health concerns. Email requests for further health information will be discarded.

The materials contained on this Web site are for informational purposes only and do not constitute health or medical advice. Use of information on this site does not create or constitute any kind of agreement or contract between you and the owners or users of this site, the owners of the servers upon which it is housed, or anyone else who is in any way connected with this site.

Many links on health.mongabay.com/health lead to other sites. health.mongabay.com/health does not sponsor, endorse or otherwise approve of the materials appearing in such sites. Nor is health.mongabay.com/health responsible for dead or misdirected links.

IF YOU NEED A LINK/TEXT REMOVED FROM THIS PAGE, PLEASE CONTACT: mongabay (at) gmail.com